Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as directed by a healthcare professional.

GNH USA supplies Montelukast Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. It is indicated for the following conditions: - Asthma: provides maintenance therapy that reduces the frequency of exacerbations and improves lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Adverse reactions may occur with any medication. The following side‑effects have been reported for Montelukast.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of queasiness that may lead to vomiting. - Cough: persistent dry or productive cough. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: depression, mood changes, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder. - Severe bronchospasm: sudden worsening of breathing difficulty.

Before initiating therapy, consider the following safety measures. - Assess asthma control: ensure baseline control before adding Montelukast. - Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Use cautiously in hepatic impairment: dose adjustment may be required for patients with liver disease. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Review concomitant medications: check for potential drug‑drug interactions. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Montelukast exposure and effectiveness. - Co‑administration with other leukotriene modifiers (e.g., zafirlukast, zileuton): increases risk of adverse hepatic and neuropsychiatric effects.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may potentiate neuropsychiatric adverse events. - Warfarin: occasional alterations in INR; monitor coagulation parameters. - Beta‑agonists (short‑acting): additive bronchodilatory effect may require dose adjustment.